Literature DB >> 11739524

Expression and release of IL-18 binding protein in response to IFN-gamma.

J Paulukat1, M Bosmann, M Nold, S Garkisch, H Kämpfer, S Frank, J Raedle, S Zeuzem, J Pfeilschifter, H Mühl.   

Abstract

IL-18 and IL-18 binding protein (IL-18BP) are two newly described opponents in the cytokine network. Local concentrations of these two players may determine biological functions of IL-18 in the context of inflammation, infection, and cancer. As IL-18 appears to be involved in the pathogenesis of Crohn's disease and may modulate tumor growth, we investigated the IL-18/IL-18BPa system in the human colon carcinoma/epithelial cell line DLD-1. In this study, we report that IFN-gamma induces expression and release of IL-18BPa from DLD-1 cells. mRNA induction and secretion of IL-18BPa immunoreactivity were associated with an activity that significantly impaired release of IFN-gamma by IL-12/IL-18-stimulated PBMC. Inducibility of IL-18BPa by IFN-gamma was also observed in LoVo, Caco-2, and HCT116 human colon carcinoma cell lines and in the human keratinocyte cell line HaCaT. Induction of IL-18BPa in colon carcinoma/epithelial cell lines was suppressed by coincubation with sodium butyrate. IFN-gamma-mediated IL-18BPa and its suppression by sodium butyrate were confirmed in organ cultures of intestinal colonic biopsy specimens. In contrast, sodium butyrate did not modulate expression of IL-18. The present data suggest that IFN-gamma may limit biological functions of IL-18 at sites of colonic immune activation by inducing IL-18BPa production. Down-regulation of IL-18BPa by sodium butyrate suggests that reinforcement of local IL-18 activity may contribute to actions of this short-chain fatty acid in the colonic microenvironment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739524     DOI: 10.4049/jimmunol.167.12.7038

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Identification of a novel human MD-2 splice variant that negatively regulates Lipopolysaccharide-induced TLR4 signaling.

Authors:  Pearl Gray; Kathrin S Michelsen; Cherilyn M Sirois; Emily Lowe; Kenichi Shimada; Timothy R Crother; Shuang Chen; Constantinos Brikos; Yonca Bulut; Eicke Latz; David Underhill; Moshe Arditi
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

2.  Interfering with interferon-γ signalling in intestinal epithelial cells: selective inhibition of apoptosis-maintained secretion of anti-inflammatory interleukin-18 binding protein.

Authors:  D Schuhmann; P Godoy; C Weiss; A Gerloff; M V Singer; S Dooley; U Böcker
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

3.  Treatment with interleukin-18 binding protein ameliorates Toxoplasma gondii-induced small intestinal pathology that is induced by bone marrow cell-derived interleukin-18.

Authors:  D Struck; I Frank; S Enders; U Steinhoff; C Schmidt; A Stallmach; O Liesenfeld; M M Heimesaat
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

4.  Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of a binding site for human IL-18 receptor alpha subunit.

Authors:  Xiangzhi Meng; Michael Leman; Yan Xiang
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

5.  The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling.

Authors:  Kuljit Parhar; Jennifer Morse; Baljinder Salh
Journal:  Int J Colorectal Dis       Date:  2006-09-29       Impact factor: 2.571

6.  Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status.

Authors:  Kazutoshi Fujita; Charles M Ewing; William B Isaacs; Christian P Pavlovich
Journal:  Int J Cancer       Date:  2010-11-16       Impact factor: 7.396

7.  The promoter of IL-18 binding protein: activation by an IFN-gamma -induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta.

Authors:  Vladimir Hurgin; Daniela Novick; Menachem Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

8.  Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients.

Authors:  A Kaser; D Novick; M Rubinstein; B Siegmund; B Enrich; R O Koch; W Vogel; S H Kim; C A Dinarello; H Tilg
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.

Authors:  Malte Bachmann; Patrick Scheiermann; Lorena Härdle; Josef Pfeilschifter; Heiko Mühl
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

10.  Failure of interferon gamma to induce the anti-inflammatory interleukin 18 binding protein in familial hemophagocytosis.

Authors:  Claudia A Nold-Petry; Thomas Lehrnbecher; Andrea Jarisch; Dirk Schwabe; Josef M Pfeilschifter; Heiko Muhl; Marcel F Nold
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.